Ember Therapeutics, Inc. announced initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee. The company said that an initial analysis of 78 of the 320 total patients enrolled in the Phase 2 trial provided evidence that even a single local dose of BMP-7 could prevent cartilage loss and had potential anabolic effects. The company is currently raising money and seeking partners for a Phase 3 pivotal trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -.--% | -.--% | -.--% |
- Stock Market
- Equities
- EMBT Stock
- News Ember Therapeutics, Inc.
- Ember Therapeutics, Inc. Announces Initial Positive Results from a Phase 2 Trial of BMP-7